These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38390812)

  • 1.
    Şahin K; Kibar A; Güneren C; Sağer MS; Sönmezoğlu K
    Mol Imaging Radionucl Ther; 2024 Feb; 33(1):54-56. PubMed ID: 38390812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
    Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
    Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
    BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of gallium-68 prostate-specific membrane antigen PET/CT and 2-[18F]fluoro-2-deoxy-D-glucose PET/CT in the detection of thyroid cancer lesions: a prospective head-to-head comparison.
    Shi Y; Feng Y; Xu L; Li W; Guan L; Zuo R; Liu S; Pang H; Wang Z
    Br J Radiol; 2023 Jul; ():. PubMed ID: 38904463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Findings Between
    Erhamamcı S; Aslan N
    Mol Imaging Radionucl Ther; 2020 Oct; 29(3):135-138. PubMed ID: 33094578
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Parghane RV; Basu S
    J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
    Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
    Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer.
    Şahin E; Elboğa U
    J Med Imaging Radiat Oncol; 2020 Dec; 64(6):756-761. PubMed ID: 32656989
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Medina-Ornelas S; García-Perez F; Estrada-Lobato E; Ochoa-Carrillo F
    Am J Nucl Med Mol Imaging; 2020; 10(3):135-142. PubMed ID: 32704404
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Gündoğan C; Ergül N; Çakır MS; Kılıçkesmez Ö; Gürsu RU; Aksoy T; Çermik TF
    Mol Imaging Radionucl Ther; 2021 Jun; 30(2):79-85. PubMed ID: 34082503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous uptake of
    Hu Y; Wang P; Dai W
    BMC Pulm Med; 2023 Mar; 23(1):73. PubMed ID: 36882747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flare on [
    Malaspina S; Ettala O; Tolvanen T; Rajander J; Eskola O; Boström PJ; Kemppainen J
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of [
    Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Gondhane AI; Verma P; Paul A
    Indian J Nucl Med; 2024; 39(1):66-68. PubMed ID: 38817716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.